Search results for: John Kauh

Items from 1 to 16 out of 16 results

article

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Anthony W. Tolcher, Jordan D. Berlin, Jan Cosaert, John Kauh, more

Cancer Chemotherapy and Pharmacology > 2017 > 79 > 4 > 673-680

Purpose LY3022859 is an anti-TGFβRII IgG₁ monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective of this phase I study was to determine a phase II dose in patients with advanced solid tumors. Secondary objectives were to assess safety and pharmacokinetics (PK). Methods LY3022859 was infused intravenously (IV) at 1.25 mg/kg over 1 h every 2 weeks (Q2W) (cohort...

article

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

Patricia M. LoRusso, Mrinal Gounder, Shadia I. Jalal, Valérie André, more

Investigational New Drugs > 2017 > 35 > 4 > 442-450

Summary Purpose Macrophage-stimulating 1-receptor (RON) is expressed on macrophages, epithelial cells, and a variety of tumors. Narnatumab (IMC-RON8; LY3012219) is a neutralizing monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP). This study assessed safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and efficacy of narnatumab in...

article

Microvessel Density Analysis in Patients with Viral Hepatitis-Related Hepatocellular Carcinoma

Amr Mohamed, Avantika Chenna, Mohamed Abdelfatah, Jain Sanjay, more

Journal of Gastrointestinal Cancer > 2015 > 46 > 2 > 104-108

Aim The aim of this study is to compare tumoral microvessel density (MVD) and overall survival in two different groups of hepatocellular carcinoma (HCC), namely, viral hepatitis-related HCC (VHr-HCC) versus non-hepatitis-related HCC (NHr-HCC). Methods Seventy-eight consecutive cases of HCC (47 hepatitis and 31 non-hepatitis cases) were studied. Microvessel numbers were assessed by staining for the...

article

Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma

Walid L. Shaib, Rahul Sharma, Edith Brutcher, Sungjin Kim, more

Journal of Surgical Oncology > 109 > 6 > 556 - 560

BackgroundAmpullary (AMP‐A) and duodenal adenocarcinomas (DA) are rare tumors. The literature regarding treatment and outcome is very limited. The objective of this project is to compare the outcomes of AMP‐A and DA. MethodsThe records for AMP‐A and DA patients between July 1995 and July 2012 at Emory University were reviewed for demographics, pathology, treatment, and survival. Survival rates were...

article

Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base

Lauren E. Colbert, William A. Hall, Dana Nickleach, Jeffrey Switchenko, more

Cancer > 120 > 4 > 499 - 506

BACKGROUNDPancreatic adenocarcinoma (PAC) has low overall survival (OS) rates and high recurrence rates following surgical resection. The role for preoperative radiation therapy (prRT) for PAC versus postoperative RT (poRT) remains uncertain. The authors used the National Cancer Data Base (NCDB) to report prRT outcomes for the largest multi‐institutional patient cohort to date. METHODSNCDB data were...

article

The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma

William A. Hall, Lauren E. Colbert, Yuan Liu, Theresa Gillespie, more

Cancer > 119 > 12 > 2350 - 2357

BACKGROUNDAdjuvant radiotherapy (A‐RT) for patients with resected pancreatic adenocarcinoma (PAC) is controversial. In the current study, the authors aim to determine whether there is an association between overall survival (OS) and A‐RT dose. METHODSNational Cancer Data Base (NCDB) data were obtained for all patients who received A‐RT for resected PAC from 1998 through 2002. Univariate and multivariate...

article

Fractionated radioimmunotherapy with ⁹⁰Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer

Allyson J. Ocean, Kenneth L. Pennington, Michael J. Guarino, Arif Sheikh, more

Cancer > 118 > 22 > 5497 - 5506

BACKGROUND:It has been demonstrated that the humanized clivatuzumab tetraxetan (hPAM4) antibody targets pancreatic ductal carcinoma selectively. After a trial of radioimmunotherapy that determined the maximum tolerated dose of single‐dose yttrium‐90‐labeled hPAM4 (⁹⁰Y‐hPAM4) and produced objective responses in patients with advanced pancreatic ductal carcinoma, the authors studied fractionated radioimmunotherapy...

article

Farnesyl transferase expression determines clinical response to the docetaxel‐lonafarnib combination in patients with advanced malignancies

John Kauh, Chantal Chanel‐Vos, Daniel Escuin, Michael P. Fanucchi, more

Cancer > 117 > 17 > 4049 - 4059

BACKGROUND:Lonafarnib (LNF) is a protein farnesyl transferase (FTase) inhibitor that has shown synergistic activity with taxanes in preclinical models and early stage clinical trials. Preclinical findings suggested tubulin acetylation and FTase expression levels may be important determinants of drug sensitivity that would help identify patient populations more likely to benefit from this regimen....

article

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer

Suresh S. Ramalingam, R. Donald Harvey, Nabil Saba, Taofeek K. Owonikoko, more

Cancer > 116 > 16 > 3903 - 3909

BACKGROUND:Everolimus is a novel inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in nonsmall cell lung cancer (NSCLC). The authors conducted a phase 1 and pharmacokinetic study of everolimus and docetaxel for recurrent NSCLC. METHODS:Patients with advanced stage NSCLC and progression after prior platinum‐based chemotherapy were eligible. Sequential cohorts were...

article

Comparison of Yttrium-90 Radioembolization and Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma

David A. Kooby, Vasili Egnatashvili, Swetha Srinivasan, Abbas Chamsuddin, more

Journal of Vascular and Interventional Radiology > 2010 > 21 > 2 > 224-230

To compare the effectiveness and toxicity of transcatheter arterial chemoembolization (chemoembolization) and yttrium-90–labeled microspheres (radioembolization) in patients with unresectable hepatocellular carcinoma (HCC).Outcomes from patients who underwent radioembolization or chemoembolization as the only treatment for unresectable HCC from 1996 to 2006 were compared. Response was assessed with...

article

A black‐white comparison of the quality of stage‐specific colon cancer treatment

Jamillah Berry, Lee Caplan, Sharon Davis, Patrick Minor, more

Cancer > 116 > 3 > 713 - 722

BACKGROUND:Several studies have attributed racial disparities in cancer incidence and mortality to variances in socioeconomic status and health insurance coverage. However, an Institute of Medicine report found that blacks received lower quality care than whites after controlling for health insurance, income, and disease severity. METHODS:To examine the effects of race on colorectal cancer outcomes...

article

Early Clinical Results from Chemoradiation with 5-Fluorouracil and Oxaliplatin for Locally Advanced Rectal Cancer

Joshua D. Lawson, John Kauh, Mary Koshy, Charles Staley, more

Clinical Colorectal Cancer > 2008 > 7 > 5 > 325-330

Preoperative chemoradiation with 5-fluorouracil (5-FU) has improved local control and resectability in patients with locally advanced rectal adenocarcinoma. The possible benefit of adding oxaliplatin is being investigated. We present background on the use of oxaliplatin as well as institutional experience assessing treatment tolerability and early outcome data. From August 2001 to August 2006,...

article

Racial Disparities in Colorectal Cancer

John Kauh, Otis W. Brawley, Mitchell Berger

Current Problems in Cancer > 2007 > 31 > 3 > 123-133

article

Gastric cancer: Standards for the 21st century

Victor Archie, John Kauh, Dennie V. Jones, Victor Cruz, more

Critical Reviews in Oncology / Hematology > 2006 > 57 > 2 > 123-131

Although the incidence of gastric cancer has been decreasing in the United States, it remains a leading cause of cancer death in the world, only lung cancer causes more deaths worldwide. The combination of relatively low prevalence, lack of pathognomonic symptoms, and lack of defined risk factors are associated with a delay in diagnosis leading to a dismal prognosis. For localized disease, surgery...

article

State of the art: Gastrointestinal malignancies in the human immunodeficiency virus (HIV) population

Mary Koshy, John Kauh, Clifford Gunthel, Melissa Joyner, more

Journal of Gastrointestinal Cancer > 2005 > 36 > 1 > 1-14

The gastrointestinal tract is one of the most common sites for the development of primary neoplasms arising in patients with pre-existing infection with the human immunodeficiency virus (HIV). Over the past decade, new information on the clinical manifestation, natural history, treatment options, and related toxicity have been reported, mostly notably the integration of highly active antiretroviral...

article

Colorectal cancer prevention

John Kauh, Jay Umbreit

Current Problems in Cancer > 2004 > 28 > 5 > 240-264

Filter options

Publication date

Set your own date range

INFONA - science communication portal

Search results for: John Kauh

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options